메뉴 건너뛰기




Volumn 30, Issue 10, 2014, Pages 2041-2050

Treatment patterns in metastatic renal cell carcinoma: A retrospective review of medical records from US community oncology practices

Author keywords

Chart review; Mammalian target of rapamycin; Metastatic renal cell carcinoma; Treatment patterns; Vascular endothelial growth factor

Indexed keywords

AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PAZOPANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN INHIBITOR; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE; VASCULOTROPIN A;

EID: 84925256390     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2014.938730     Document Type: Review
Times cited : (36)

References (27)
  • 3
    • 37549072095 scopus 로고    scopus 로고
    • Fort Washington, PA: National Comprehensive Cancer Network, Available at: Last accessed 14 May 2014
    • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology - Kidney Cancer version 3.2014. Fort Washington, PA: National Comprehensive Cancer Network, 2014. Available at: http://www.nccn.org/professionals/physician-gls/pdf/kidney.pdf [Last accessed 14 May 2014]
    • (2014) NCCN Clinical Practice Guidelines in Oncology - Kidney Cancer Version 3.2014
  • 4
    • 70249097380 scopus 로고    scopus 로고
    • Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:3312-18
    • (2009) J Clin Oncol Off J Am Soc Clin Oncol , vol.27 , pp. 3312-3318
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 5
    • 77952300540 scopus 로고    scopus 로고
    • Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
    • Escudier B, Bellmunt J, Né grier S, et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:2144-50
    • (2010) J Clin Oncol Off J Am Soc Clin Oncol , vol.28 , pp. 2144-2150
    • Escudier, B.1    Bellmunt, J.2    Né Grier, S.3
  • 6
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    • Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 7
    • 77949890945 scopus 로고    scopus 로고
    • Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
    • Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:1061-8
    • (2010) J Clin Oncol Off J Am Soc Clin Oncol , vol.28 , pp. 1061-1068
    • Sternberg, C.N.1    Davis, I.D.2    Mardiak, J.3
  • 8
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 9
    • 77956227464 scopus 로고    scopus 로고
    • Phase 3 trial of everolimus for metastatic renal cell carcinoma: Final results and analysis of prognostic factors
    • Motzer RJ, Escudier B, Oudard S, et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010;116:4256-65
    • (2010) Cancer , vol.116 , pp. 4256-4265
    • Motzer, R.J.1    Escudier, B.2    Oudard, S.3
  • 10
    • 82755183572 scopus 로고    scopus 로고
    • Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised phase 3 trial
    • Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011;378:1931-9
    • (2011) Lancet , vol.378 , pp. 1931-1939
    • Rini, B.I.1    Escudier, B.2    Tomczak, P.3
  • 11
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma
    • Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 12
    • 84899679988 scopus 로고    scopus 로고
    • Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma
    • Hutson TE, Escudier B, Esteban E, et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 2014;32:760-7
    • (2014) J Clin Oncol Off J Am Soc Clin Oncol , vol.32 , pp. 760-767
    • Hutson, T.E.1    Escudier, B.2    Esteban, E.3
  • 13
    • 84896713052 scopus 로고    scopus 로고
    • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial
    • Motzer RJ, Porta C, Vogelzang NJ, et al. Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 2014;15:286-96
    • (2014) Lancet Oncol , vol.15 , pp. 286-296
    • Motzer, R.J.1    Porta, C.2    Vogelzang, N.J.3
  • 14
    • 80255141916 scopus 로고    scopus 로고
    • Sequence therapy in patients with metastatic renal cell carcinoma: Comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors
    • Busch J, Seidel C, Kempkensteffen C, et al. Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors. Eur Urol 2011;60:1163-70
    • (2011) Eur Urol , vol.60 , pp. 1163-1170
    • Busch, J.1    Seidel, C.2    Kempkensteffen, C.3
  • 15
    • 84868515033 scopus 로고    scopus 로고
    • Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma
    • Chen C-C, Hess GP, Liu Z, et al. Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma. Clin Genitourin Cancer 2012;10:256-61
    • (2012) Clin Genitourin Cancer , vol.10 , pp. 256-261
    • Chen, C.-C.1    Hess, G.P.2    Liu, Z.3
  • 16
    • 84866294721 scopus 로고    scopus 로고
    • Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: Evidence from US community oncology clinics
    • Feinberg BA, Jolly P, Wang S-T, et al. Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics. Med Oncol Northwood Lond Engl 2012;29:786-94
    • (2012) Med Oncol Northwood Lond Engl , vol.29 , pp. 786-794
    • Feinberg, B.A.1    Jolly, P.2    Wang, S.-T.3
  • 17
    • 84880267774 scopus 로고    scopus 로고
    • Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI
    • Park K, Lee J-L, Park I, et al. Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VEGF TKI. Med Oncol Northwood Lond Engl 2012;29:3291-7
    • (2012) Med Oncol Northwood Lond Engl , vol.29 , pp. 3291-3297
    • Park, K.1    Lee, J.-L.2    Park, I.3
  • 18
    • 77955470097 scopus 로고    scopus 로고
    • Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy
    • Vickers MM, Choueiri TK, Rogers M, et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor-targeted therapy. Urology 2010;76:430-4
    • (2010) Urology , vol.76 , pp. 430-434
    • Vickers, M.M.1    Choueiri, T.K.2    Rogers, M.3
  • 19
    • 84867519699 scopus 로고    scopus 로고
    • Immunotherapy and targeted therapies in metastatic renal cell carcinoma: Is there a preferred sequence?
    • Giuliani J, Drudi F. Immunotherapy and targeted therapies in metastatic renal cell carcinoma: is there a preferred sequence? Cancer Biother Radiopharm 2012;27:513-18
    • (2012) Cancer Biother Radiopharm , vol.27 , pp. 513-518
    • Giuliani, J.1    Drudi, F.2
  • 20
    • 79955122842 scopus 로고    scopus 로고
    • Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action
    • Larkin J, Swanton C, Pickering L. Optimizing treatment of metastatic renal cell carcinoma by changing mechanism of action. Expert Rev Anticancer Ther 2011;11:639-49
    • (2011) Expert Rev Anticancer Ther , vol.11 , pp. 639-649
    • Larkin, J.1    Swanton, C.2    Pickering, L.3
  • 21
    • 84871514484 scopus 로고    scopus 로고
    • Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: State-of-the-science
    • Porta C, Sabbatini R, Procopio G, et al. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther 2012;12:1571-7
    • (2012) Expert Rev Anticancer Ther , vol.12 , pp. 1571-1577
    • Porta, C.1    Sabbatini, R.2    Procopio, G.3
  • 22
    • 84896470513 scopus 로고    scopus 로고
    • Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: A US medical record review
    • Wong MK, Yang H, Signorovitch JE, et al. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review. Curr Med Res Opin 2014;30:537-45
    • (2014) Curr Med Res Opin , vol.30 , pp. 537-545
    • Wong, M.K.1    Yang, H.2    Signorovitch, J.E.3
  • 23
    • 79958734431 scopus 로고    scopus 로고
    • An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples
    • Di Lorenzo G, Casciano R, Malangone E, et al. An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. Expert Opin Pharmacother 2011;12:1491-7
    • (2011) Expert Opin Pharmacother , vol.12 , pp. 1491-1497
    • Di Lorenzo, G.1    Casciano, R.2    Malangone, E.3
  • 24
    • 84878495150 scopus 로고    scopus 로고
    • A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC)
    • Heng D. A population-based overview of sequences of targeted therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 2012;30(Suppl 5): abstr 387
    • (2012) J Clin Oncol , vol.30
    • Heng, D.1
  • 25
    • 84887021715 scopus 로고    scopus 로고
    • Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review
    • Yang H, Wong MKK, Signorovitch JE, et al. Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: a retrospective U.S. chart review. J Clin Oncol 2012;30:(suppl): abstr 4612
    • (2012) J Clin Oncol , vol.30
    • Yang, H.1    Wong, M.K.K.2    Signorovitch, J.E.3
  • 26
    • 84995400026 scopus 로고    scopus 로고
    • Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC)
    • Ryan CJ, Green MR, Britton SL, et al. Second-line prescribing preferences (PPrefs) of U.S.-based medical oncologists (MOs) following first-line TKI in patients with metastatic clear cell renal cell carcinoma (mccRCC). J Clin Oncol 2014;32(suppl 4): abstr 492
    • (2014) J Clin Oncol , vol.32
    • Ryan, C.J.1    Green, M.R.2    Britton, S.L.3
  • 27
    • 84908641368 scopus 로고    scopus 로고
    • Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Synthesis of findings from two multi-practice chart reviews in the United States
    • in press
    • Signorovitch JE, Vogelzang NJ, Pal SK, et al. Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States. Curr Med Res Opin 2014, in press
    • (2014) Curr Med Res Opin
    • Signorovitch, J.E.1    Vogelzang, N.J.2    Pal, S.K.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.